PTCT
HealthcarePTC Therapeutics, Inc.
$76.76
+$0.02 (+0.03%)
Jan 5, 2026
Price History (1Y)
Analysis
PTC Therapeutics, Inc. is a biotechnology company in the healthcare sector with a market capitalization of $6.16 billion and revenue of $1.78 billion. The company employs 939 individuals across its operations. The financial health of PTC Therapeutics reveals profitability through its gross margin at 71.7% and profit margin at 42.3%. Additionally, the company's return on assets stands at 25.7%, indicating efficient asset utilization. On the balance sheet side, the company has cash reserves of $1.71 billion and debt amounting to $2.49 billion. PTC Therapeutics' valuation is characterized by a P/E ratio (TTM) of 8.93 and forward P/E of -91.38. The price to sales ratio stands at 3.46, while the EV/EBITDA ratio is 7.27. Notably, the company has been experiencing revenue growth at a rate of 7.2% year-over-year.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About PTC Therapeutics, Inc.
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich's ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey.
Visit website →Key Statistics
- Market Cap
- $6.16B
- P/E Ratio
- 8.93
- 52-Week High
- $87.50
- 52-Week Low
- $35.95
- Avg Volume
- 1.49M
- Beta
- 0.49
Company Info
- Industry
- Biotechnology
- Exchange
- NMS
- Country
- United States
- Employees
- 939